#T2D➡️
LightNews LightNews
adapubs.bsky.social
HTD1801, a first-in-class, novel therapy, significantly reduced HbA1c and improved cardiometabolic and inflammatory markers in participants with #T2D.

Read here ➡️ doi.org/10.2337/dc26-0739
The image is an infographic detailing the effects of HTD1801 on type 2 diabetes markers. It includes sections on objective, study design, results, and conclusion. A graph shows a decrease in HbA1c levels over time. Key measurements include glucose metabolism (HbA1c, FPG), lipid metabolism (non-HDL-c), and inflammation (hs-CRP). The study utilized a randomized, placebo-controlled method.
October 6, 2026 at 11:50 AM
diabresearch-dzd.bsky.social
🥗 A healthy diet lowers the risk of type 2 diabetes. But do we all benefit equally?
New DZD + DIfE research suggests that epigenetic factors may influence how strongly diet protects against diabetes, opening new possibilities for precision prevention.
➡️https://t1p.de/115nl
#Prevention #T2D
September 22, 2026 at 2:11 PM
adapubs.bsky.social
Longitudinal protein measurements identify additional novel disease biomarkers and disparate biological pathways compared with single measurement analyses. #T2D

Read here ➡️ doi.org/10.2337/db26-0148
The image is a scientific diagram comparing single-time point and longitudinal repeated proteomics analyses from MESA and UK Biobank (UKB) studies. It shows the process and data flow for incident type 2 diabetes (T2D) biomarker analysis, highlighting pathways and comparison analyses. The left side details the MESA study with proteomics measurements across exams, while the right side shows UKB with a baseline measurement. Additional diagrams include a Mendelian randomization chart and a Venn diagram for pathway enrichment analyses.
September 17, 2026 at 10:50 PM
idfe.bsky.social
🙌At our #EASD2026 symposium, T2D Advocate, Erik Werson will highlight why access to diabetes education is key to empowering people living with all types of diabetes with the knowledge, skills & confidence to effectively manage their condition.

➡️ idf.org/europe/congr...
September 15, 2026 at 9:58 AM
adapubs.bsky.social
Screening for disordered eating, emotion-focused coping strategies, and culturally responsive guidance may be a missing link in improving glycemic control in Black adults with type 2 diabetes.

Read here ➡️doi.org/10.2337/doc26-0080
The flowchart illustrates the pathways to binge eating influenced by socioecological contexts. It starts with layered factors like health care and social conditions, leading to a "T2D Diagnosis." Arrows show progression through "Negative Emotions" and "Emergent Emotions & Externalized Responses," contributing to "Binge Eating." The chart highlights feedback loops involving perception of restriction, leading to active food restriction, then to urges impacting binge behaviors. GOODE AND ASSOCIATES.
September 14, 2026 at 3:45 PM
adapubs.bsky.social
Peripheral bone loss was similar in those with and without diabetes, thus bone loss does not explain the higher fracture risk in older adults with #T2D.

Read here ➡️ doi.org/10.2337/dc26-0846
A scientific poster titled "Peripheral Bone Changes Alone May Not Explain Increased Fracture Risk Reported in Some Older Adults With Type 2 Diabetes." The layout includes three main sections: "Purpose," "Methods," and "No Difference in 8-Year % Change by Glycemic Status." The "Purpose" section explains the goal of understanding fracture risk in older adults with type 2 diabetes. The "Methods" section details the study, including data from 769 participants in the Framingham Study and type 2 diabetes classification using HbA1c levels. The "No Difference" section presents a graph comparing glycemic status and bone density changes over eight years, with data points for Ct.BMD, Tb.BMD, Ct.Th, and Tb.Th.
September 14, 2026 at 1:45 AM
adapubs.bsky.social
Compared with no gestational diabetes mellitus, GDM was significantly associated with higher diabetes risk, with recurrent GDM doubling the risk.

Read here ➡️ doi.org/10.2337/dc26-0856

The image is an infographic titled "GDM: Recurrence and Risk of Future T2D" from the KPSC Retrospective Cohort Study involving 326,115 mothers. It shows that 12.60% were diagnosed with gestational diabetes mellitus (GDM) during their first pregnancy, and 50.25% with subsequent pregnancies. The diabetes risk increases to a 5-fold higher T2D risk with a single GDM and nearly 10-fold with recurrent GDM. The median follow-up time is 6.2 years. Race and ethnicity impact high-risk screening recommendations.
September 12, 2026 at 7:55 PM
idfe.bsky.social
📣 Final call! The T2GETHER Summit 2026 deadline has been extended to Sept 18!

🗣️ Do you live with #T2D and want to strengthen your advocacy skills?

📍 Brussels | Oct 9–11 ✨ Free registration + travel & accommodation covered by IDF Europe.

➡️ Apply: media.idf.org/media/upload...
September 8, 2026 at 1:16 PM
adapubs.bsky.social
Among adults with #T2D on GLP-1RAs, oxycodone initiation was associated with a higher 30-day GI risk than hydrocodone or tramadol; risks were similar between hydrocodone and tramadol.

Read here ➡️ doi.org/10.2337/dc26-0757
This image is an infographic detailing a study on opioid use and gastrointestinal outcomes in adults with type 2 diabetes using GLP-1RA therapy. It includes sections on population and setting, exposure, outcomes, and results. A graph shows relative risks of opioid use (oxycodone and tramadol) on gastrointestinal outcomes like constipation, bowel obstruction, and gastroparesis. A conclusion notes higher risk with oxycodone. Data sources include Medicare FFS and MarketScan.
September 8, 2026 at 12:15 PM
adapubs.bsky.social
Metabolomic profiling identified distinct prediabetes subgroups with different risks of T2D, CVD, and CKD. These findings may support metabolite-informed risk stratification and targeted dietary prevention. #Diabetes #Metabolomics

Read here ➡️ doi.org/10.2337/db26-0218
A diagram shows a flowchart of a UK Biobank study with 24,638 participants and 251 NMR metabolites. It illustrates cluster analyses resulting in three groups: Low-risk (32%) with green figures, Intermediate-risk (45%) with orange figures, and High-risk (23%) with red figures. Arrows connect these clusters to three circles representing "Dietary patterns," "Long-term outcomes" (T2D, CVD, CKD), and "Mendelian randomization." Abbreviations: CKD for chronic kidney disease, CVD for cardiovascular disease, NMR for nuclear magnetic resonance, T2D for type 2 diabetes.
September 3, 2026 at 9:25 PM
idfe.bsky.social
🙌At our #EASD2026 symposium, Prof. Michael Trenell will present insights on the role of digital health platforms in #T2D #education and self-management support, and how to scale their adoption within healthcare systems.

➡️Discover the programme: idf.org/europe/congr...
August 26, 2026 at 6:21 AM
idfe.bsky.social
📣 Applications are open for the #T2GETHER Summit 2026!

🗣️ Live with #T2D? Join a European community, build advocacy skills & share your voice.

📍 Brussels | Oct 9-11
💙 Travel & accommodation covered
⏰ Apply by Sept 7

➡️ Apply now: idf.org/europe/our-n...
August 20, 2026 at 8:31 AM
nephjc.bsky.social
3/10
Methods 🛠️
🇳🇱 Multicenter, double-blind RCT (n=784)
👥Elective cardiac surgery
💊Dapa 10 mg vs placebo
🗓️Day −1➡️ POD2 (4 doses)
🎯1°outcome: KDIGO AKI ≤ 7days (Cr or UOP)
Cohort: 97% White, 76% male, median eGFR 80. 12% T2D.
Not our typical high-risk CKD population.
August 19, 2026 at 1:09 AM
adapubs.bsky.social
Blood-based DNA methylation (DNAm) biomarkers improve short-term risk stratification for major adverse cardiovascular events in individuals with #T2D.

Read here ➡️ https://doi.org/10.2337/dc26-0738
August 17, 2026 at 2:10 AM
adapubs.bsky.social
Glucose-dependent insulinotropic polypeptide remains biologically active in #T2D and pharmacological doses modulate glucose metabolism and cardiovascular function.

Read here ➡️ doi.org/10.2337/db26-0267
A diagram illustrating a study on the effects of pharmacological GIP in type 2 diabetes. It includes a timeline, showing IV GIP or saline infusion over 210 minutes. Symbols represent participants and data on age, BMI, and HbA1c levels. Illustrated organs show observed effects with arrows indicating changes: upward for blood pressure, heart rate, insulin, glucagon, and insulin sensitivity, and downward for whole-body glucose disposal.
August 14, 2026 at 9:50 PM
adapubs.bsky.social
🚨 A new month, a new Care on Air! Where #podcast hosts Mike & Alice discuss the latest and greatest of Diabetes Care.

🎧 https://diabetescareonair.libsyn.com/site

In this ep:
✨Automated Insulin Delivery & Pregnancy
✨GIP in T2D & Obesity
✨& more!

Full issue ➡️
http://diabetesjournals.org/care
The logo for the Diabetes Care On Air podcast, featuring a black white image of the hosts, a "listen and subscribe" call to action, and the insignia of the American Diabetes Association
August 12, 2026 at 2:15 PM
roole.fr
Éclipse solaire : 5 panoramas exceptionnels à rejoindre en voiture pour admirer le spectacle
➡️ https://l.roole.fr/T2d
August 11, 2026 at 4:01 PM
adapubs.bsky.social
Sarcopenic obesity was associated with higher #T2D risk than obesity or sarcopenia alone, supporting integrated assessment of muscle health and adiposity in T2D risk stratification.

Read here ➡️ doi.org/10.2337/dc26-0797
A diagram titled "Sarcopenic Obesity and Risk of Incident Type 2 Diabetes" from the UK Biobank study. It summarizes a study with 497,097 participants. The diagram includes a flowchart and key findings, showing the hazard ratios for developing diabetes based on different conditions: sarcopenic obesity (1.61), obesity only (1.35), and sarcopenia only (1.34). A chart illustrates transitions between baseline and follow-up assessments, with corresponding risk assessments. The conclusion notes a strong link between sarcopenic obesity and a higher risk of diabetes, emphasizing the importance of muscle health.
August 6, 2026 at 8:30 PM
adapubs.bsky.social
Pharmacist-led pre-visit planning may improve access to guideline-directed therapy and may support glycemic improvement in adolescents and young adults with #T2D.

Read here ➡️ doi.org/10.2337/doc26-0019
Graph depicting the acceptance rate over PDSA cycles. The vertical axis shows acceptance rate in percentage, and the horizontal axis shows PDSA cycle numbers 1 to 6. Data points are plotted at (1, 40.0%), (2, 0.0%), (3, 20.0%), (4, 20.0%), and (5, 49.1%), connected by lines forming a V shape followed by a rise.
August 6, 2026 at 8:45 PM
adapubs.bsky.social
In #T2D on insulin and #hemodialysis, %TBR was low & not affected by #rtCGM. Compared to capillary glucose testing, %TIR, mean glucose and %TAR improved during the #rtCGM intervention.

Read here ➡️ doi.org/10.2337/dc26-0404
This image is an infographic about a clinical trial on real-time continuous glucose monitoring (rtCGM) for people with type 2 diabetes and end-stage kidney failure. It includes sections on the study's objective, outcomes, design, and conclusions. Bars and graphs show glycemic ranges, with multicolored sections representing the different ranges. The trial duration is noted as 180 days, with specific phases like randomization and washout. The data is presented clearly with labels and color coding for readability.
July 30, 2026 at 8:55 PM
adapubs.bsky.social
T2D screening in South Asian patients at lower BMI thresholds and individualized management approaches through a cultural lens should be considered. Research should be expanded in the South Asian population.

Read here ➡️ doi.org/10.2337/doc26-0007
Diagram illustrating factors related to Type 2 Diabetes (T2D) in South Asian individuals, including South Asian Diet, Insulin Resistance, β-Cell Dysfunction, Thin-Fat Phenotype, Physical Inactivity, Low Body Weight, and Genetics. Each factor is connected with arrows to the central topic.
July 29, 2026 at 9:50 PM
idfe.bsky.social
🧠Yesterday was #WorldBrainDay! #PwD are at increased risk of cognitive impairment. New findings from the Horizon 2020-funded RECOGNISED project suggest retinal assessments in people living with T2D could support earlier identification.
➡️Read more: idf.org/europe/news/...
July 23, 2026 at 11:55 AM
adapubs.bsky.social
Crossover trial: melatonin impairs glucose tolerance in the common MTNR1B T2D risk carriers by reducing first-phase β-cell response & insulin feedback—supporting genotype-tailored melatonin timing.

Read here ➡️ https://doi.org/10.2337/dc26-0164

This image is an infographic titled "Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant." It shows how the MTNR1B risk G-allele influences glucose metabolism. The left side features images of a noncarrier and a carrier, with text explaining MTNR1B status. The middle section depicts a randomized, crossover, double-blind study involving melatonin and a placebo. The right section displays results with charts showing increased glucose levels and decreased insulin response in carriers compared to noncarriers. A conclusion box summarizes study findings.
July 20, 2026 at 12:15 AM
goggledocs.bsky.social
📢 ACR in Obesity (Ob): Are we under Dx albuminuria?

🔹 Ob ⤴️ creatinine excretion = ACR underestimates albuminuria

🔸 Delay Rx in #CKD & #T2D—esp. RASi, SGLT2i, nsMRA

🔹 Bias = in ♂ & ⤴️ muscle

🔸 Review calls➡️♀️♂️ cutoffs or estimated AER (eAER)

🕓 to rethink ACR thresholds in Ob❓

🔗 ggdocs.co/l1htvt
Redirecting
ggdocs.co
March 16, 2025 at 10:49 AM
goggledocs.bsky.social
🚨Small molecule #GLP1 are coming, soon‼️

🔹orforglipron (Lilly) will be 🥇
📍P3 trial data this year ➡️ launch early 2026
🔗 ggdocs.co/8kjbfv

🔸RGT-075 (Regor) ?next
📍P2a data ⤵️wt % in 12w, also ⤵️HbA1c
🔗 ggdocs.co/hg6b56

👉 #GLP1 easy & cheap to produce

#obesity #T2D
🙏🏻 @pharmrj.pharmsky.app
Regor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small Molecule GLP-1R Agonist, and Begins Phase 2b Study in the US for the Treatment of Obesity
/PRNewswire/ -- Regor Therapeutics Group ("Regor"), a privately-held clinical-stage global biopharmaceutical company, announced topline results from its Phase...
ggdocs.co
January 14, 2025 at 6:41 PM